Anvisa cria grupo de trabalho para investigar vacina da dengue do Butantan
AI Summary
Brazil's health regulatory agency, Anvisa, has formed a task force to thoroughly investigate adverse events linked to the Butantan-DV dengue vaccine after 42 severe reactions, including two deaths. This move, formalized in portaria 715/2026, underscores the urgency to ensure vaccine safety and public trust. The formation of this group highlights the importance of rigorous post-market surveillance in safeguarding public health, especially for widely distributed vaccines.
Original Source
Read the full article at Redir →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.